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Abstract 
Background: Active surveillance (AS) is a management option for men diagnosed with lower risk prostate cancer. 
There is wide variation in all aspects of AS internationally, from patient selection to investigations and follow-up inter-
vals, and a lack of clear evidence on the optimal approach to AS. This study aimed to provide guidance for clinicians 
from an international panel of prostate cancer experts.
Methods: A modified Delphi approach was undertaken, utilising two rounds of online questionnaires followed by 
a face-to-face workshop. Participants indicated their level of agreement with statements relating to patient selection 
for AS via online questionnaires on a 7-point Likert scale. Factors not achieving agreement were iteratively developed 
between the two rounds of questionnaires. Draft statements were presented at the face-to-face workshop for discus-
sion and consensus building.
Results: 12 prostate cancer experts (9 urologists, 2 academics, 1 radiation oncologist) participated in this study from 
a range of geographical regions (4 USA, 4 Europe, 4 Australia). Complete agreement on statements presented to the 
participants was 29.4% after Round One and 69.0% after Round Two. Following robust discussions at the face-to-face 
workshop, agreement was reached on the remaining statements. PSA, PSA density, Multiparametric MRI, and system-
atic biopsy (with or without targeted biopsy) were identified as minimum diagnostic tests required upon which to 
select patients to recommend AS as a treatment option for prostate cancer. Patient factors and clinical parameters 
that identified patients appropriate to potentially receive AS were agreed. Genetic and genomic testing was not rec-
ommended for use in clinical decision-making regarding AS.
Conclusions: The lack of consistency in the practice of AS for men with lower risk prostate cancer between and 
within countries was reflected in this modified Delphi study. There are, however, areas of common practice and agree-
ment from which clinicians practicing in the current environment can use to inform their clinical practice to achieve 
the best outcomes for patients.
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Background
Prostate cancer incidence globally is increasing and pros-
tate cancer specific mortality is decreasing, in part due to 
an increase in the diagnosis of low-risk prostate cancer 
[1]. The risk of disease progression in men with local-
ised prostate cancer at diagnosis is mainly determined 
by the Gleason grade, a histopathological prostate cancer 
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grading system [2]. Patients with localised Gleason grade 
3 + 3 prostate cancer have almost no risk of metastatic 
progression, and the risk increases with higher Glea-
son grades [3]. Active Surveillance (AS) is a treatment 
option for patients diagnosed with localised prostate 
cancer with low-risk of disease progression. AS involves 
proactive, regular monitoring to defer or avoid radical 
treatments that have significant associated morbidity, 
such as prostatectomy or radiotherapy [4]. Large single 
centre [5, 6] studies, multicentre [7, 8] AS cohorts, and 
a large randomised controlled trial of active monitoring 
versus radical treatment [9] have shown that the risk of 
disease progression and prostate cancer mortality is very 
low in men with low-risk disease after long-term follow-
up. These findings were relatively consistent, despite 
each study employing different AS eligibility criteria and 
protocols.
A major challenge for urologists and prostate can-
cer multidisciplinary teams in identifying appropriate 
patients for AS is the accurate diagnosis and grading 
of prostate cancer. The traditional diagnostic pathway 
using prostate specific antigen (PSA) testing followed 
by transrectal ultrasound guided biopsy (TRUS), which 
published AS studies to date have largely relied upon, 
is known to over-detect low-grade prostate cancer and 
under-detect high grade prostate cancer [10]. The limita-
tions of the traditional pathway can be seen in the rates of 
diagnoses in men with previous negative biopsies under-
going repeat TRUS biopsies [11] and the reclassification 
of 25–33% of patients on AS to higher grade disease after 
initial diagnosis in cohort studies [7, 8]. Multiparametric 
magnetic resonance imaging (mpMRI), which is a rela-
tively new imaging modality that can be used in the pre-
biopsy setting to detect lesions in the prostate and guide 
targeted biopsy, is a more accurate test [10, 12] whose 
role in AS is still being defined [13, 14]. Numerous bio-
markers and genetic mutations have been identified as 
potentially being useful for prostate cancer risk stratifica-
tion and prognostication, but the evidence base remains 
heterogeneous and weak [15].
Given the challenges in accurately diagnosing and clas-
sifying prostate cancer and the range of AS strategies 
that have been trialled to date, the wide variation in AS 
that currently exists in clinical practice is probably not 
surprising. Numerous studies have shown significant 
variation in all aspects of AS, including patient selection, 
follow-up protocols, and criteria for switching to radical 
treatments. This variation in AS practice has been shown 
to exist between institutions, regionally within countries, 
and in national and international guidelines [16–19]. 
Whilst survey data shows that the majority of clinicians 
perceive AS to be effective [20], the optimal approach to 
selecting patients for AS is still unknown. This modified 
Delphi study aimed to develop consensus on practical 
guidance for clinicians in the appropriate selection of 
men with lower risk prostate cancer to recommend active 
surveillance.
Methods
This study followed a modified Delphi method [21] to 
achieve consensus amongst a group of international pros-
tate cancer experts (see Fig.  1). Participants of the 20th 
Asia–Pacific Prostate Cancer Conference were invited to 
take part in the study via email. Basic demographic infor-
mation was collected from all participants. The aim of 
recruitment was to include at least one participant from 
each continent represented at the conference.
A review of the literature was undertaken to under-
stand the current practice of AS in different healthcare 
systems, and previous attempts to achieve consensus in 
aspects of AS. Specifically, individual patient and clinical 
Fig. 1 Study flow diagram
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factors, and criteria for offering AS, were searched for 
and extracted from recently published studies of AS for 
prostate cancer. Any factors with at least some evidence 
for discrimination and patient selection for AS were 
included in the online questionnaires to ensure no rel-
evant factors were missed. Key references were used to 
inform the development of the online questionnaires and 
the consensus statements.
Two rounds of anonymised questionnaires (see Addi-
tional files 1, 2: supplementary files) were delivered to 
participants using a secure online platform between May 
and July 2019. Participants were sent a link via email to 
complete the questionnaires, which remained open to 
responses for two weeks. After each round of question-
naires, the participants received a summary feedback 
report and were given the opportunity for comment and 
suggestions to feed into the iterative process of refining 
statements that had not yet achieved consensus.
Participants responded to individual statements about 
factors affecting decision-making to offer AS on a 7-point 
Likert scale. Agreement for each statement was defined 
by a mean score of 5.5 or higher on the scale. Disagree-
ment for each statement occurred if > 33% of respondents 
were divergent in their views [22]. Participants were also 
asked to rank the relative importance of individual fac-
tors in decision-making for AS, and build their preferred 
criteria for AS. Free text comments were also analysed to 
inform the draft consensus statements for discussion and 
agreement.
The consensus workshop was held at the 20th Asia–
Pacific Prostate Cancer Conference in Melbourne, Aus-
tralia. The majority (n = 9) of Delphi study participants 
were in attendance. Audio-visual recording of the work-
shop was undertaken to document the discussions of the 
participants in full. The workshop was opened with a 
summary of the results of the online questionnaires and 
the areas where consensus had yet to be achieved. Draft 
statements were discussed and developed in the work-
shop, and the final criteria for AS were circulated to all 
participants following the workshop for agreement.
Results
12 international prostate cancer experts participated in 
this modified Delphi study. Most participants were prac-
ticing urologists [9] and most were male [10]. There were 
4 participants from each of the continents represented at 
the 20th Asia–Pacific Prostate Cancer Conference (North 
America, Europe, and Australia). One participant did not 
complete Round Two of the questionnaires, and three 
participants were not present for the face-to-face work-
shop. All participants reviewed the final AS criteria prior 
to publication. All eligible participants who were invited 
consented to participate in this study.
The initial questionnaire presented participants with 
49 statements regarding individual clinical factors affect-
ing decision-making for prostate cancer. Clear consen-
sus was achieved on 29.4% of the statements. A ranking 
exercise of the relative importance of individual clinical 
factors showed that participants felt the Gleason score/
Gleason Grade Group provided the most useful data for 
decision-making in relation to offering active surveillance 
for prostate cancer, however it was emphasised by multi-
ple participants that the decision is multifactorial. Table 1 
shows the results of an initial exercise in designing an AS 
protocol.
Utilising data obtained from Round 1 and participant 
feedback, a further 12 factors were added for possible 
inclusion in the Round 2 questionnaire. Consensus was 
achieved on 69% of all statements at the conclusion of 
this round of the study. 82% of participants also agreed 
that a combination of criteria should be met for recom-
mending AS; one participant felt all criterion in any list 
should be met and one indicated at least one criterion 
should be met. After participants were presented with 
the Round 2 results and given the opportunity for fur-
ther comment, a collection of draft consensus statements 
were prepared and circulated prior to the face-to-face 
workshop. An open meeting utilising facilitated discus-
sion was conducted with the study participants, focusing 
on the areas where consensus had not yet been reached 
and developing the list of consensus statements into a set 
of criteria for recommending AS for patients with pros-
tate cancer. The discussions were synthesised into final 
consensus statements, which were circulated for com-
ment and approval after the workshop (See Table 2).
Discussion
This modified Delphi study sought to address current 
issues surrounding the consistency and quality of care 
for men with prostate cancer who could potentially ben-
efit from active surveillance as a treatment modality. 
The panel considered a range of issues relating to AS, 
including underlying principles of treatment, diagnostic 
Table 1 Factors for  selection of  patients for  AS  achieving 
agreement after Round 1 questionnaire
PSA < 10 ng/mL
Clinical stage < T2
Systematic and/or Targeted biopsy approach
12 cores taken at biopsy
Gleason score 3 + 4 or lower
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information, and risk assessment. The agreed crite-
ria outline a relatively flexible approach to offering AS, 
reflecting the current uncertainties and evolving evi-
dence around the optimal use and delivery of AS.
Key principles of active surveillance
There were a number of key principles on which the 
participants held clear agreement. The panel agreed 
that a patient with prostate cancer should be in a rea-
sonable state of health in order to benefit from active 
surveillance, and that their life expectancy, medical co-
morbidities, suitability for radical treatment, and treat-
ment preferences should all be taken into consideration 
for management decision-making. In the context of the 
known limitations of the current prostate cancer diag-
nostic tests, with the potential for over-diagnosis and 
misclassification of prostate cancer, a rigorous approach 
to AS is critical to avoid over-treatment and the associ-
ated adverse effects for men. The panel also felt that an 
optimal AS follow-up protocol would be able to accu-
rately identify disease progression to inform decisions 
about switching to radical treatment.
Diagnostic information
The importance of accurate diagnostic information was 
discussed at length by the panel, underlying the key role 
that this data plays in identifying men who are poten-
tially appropriate for AS. This is exemplified in the two 
cases captured in Table 3. The index of suspicion follow-
ing a negative mpMRI and the need to consider biopsy in 
these men with some similar characteristics is clinically 
different, and underlines the importance of thorough 
investigation to make a clear diagnosis of prostate cancer. 
There was strong consensus on the minimum set of diag-
nostic tests needed to inform the decision about offer-
ing AS (see Table 2), however other available tests such 
as Free:Total PSA ratio and the number of positive cores 
were more contentious. Multiparametric MRI was felt to 
be of high importance, and is increasingly being used as 
a diagnostic test for prostate cancer; however pre-biopsy 
mpMRI has not yet been recommended in many national 
level guidelines [17, 23].
The number of positive cores and positive core length 
can be influenced by the location of the biopsy sam-
pling and the total number of cores taken, and the rela-
tive importance of these factors was not agreed upon 
by the panel. Most prostate cancer guidelines do not 
include the number of positive cores or the percentage 
Table 2 Final criteria for prostate cancer patient selection for AS agreed by Delphi panel
Criteria for recommending active surveillance as a treatment option for patients with localised prostate cancer




 Suitability to undergo radical treatment for prostate cancer
 Treatment preferences
The results of the following tests should be considered in making a decision whether to recommend active surveillance (as a minimum):
 Prostate Specific Antigen (PSA)
 PSA density
 Multiparametric MRI (mpMRI)
 Prostate biopsy (with a minimum of 12 cores from a systematic approach ± 2–4 targeted cores from an MRI visible lesion)
Patients meeting all of the following criteria can be recommended active surveillance as a treatment option. Patients meeting five of the following criteria could 
also be considered for active surveillance:
 PSA less than or equal to 10 ng/mL
 PSA density less than or equal to 0.15 ng/mL2
 Clinical stage less than or equal to T1c
 PIRADS score less than 3
 Gleason score 3 + 3/Gleason Grade Group of 1
 No family history of prostate cancer
Patients meeting the following criteria should not be recommended active surveillance as a treatment option:
 Gleason score 4 + 3/Gleason Grade Group ≥ 3
 Genetic and genomic testing (such as Prostarix or SNP profiles) should not be used to inform decisions about active surveillance
Table 3 Clinical scenarios of  two similar patients 
with different prostate cancer risk
Patient 1 Patient 2
Age 50 50
PSA 10 10
PIRADS 2.1 1 1
Free:Total PSA Low High
Family history of prostate cancer Negative Negative
Prostate volume 20 cc 120 cc
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of cancer per core in prostate cancer risk definitions, 
although many individual centres still include these 
measures in their AS eligibility criteria [17, 18]. The 
panel generally felt that Transrectal Ultrasound-guided 
biopsy (TRUS) alone was not sufficiently accurate to be 
used as the basis for histopathological assessment of a 
prostate cancer, and ideally a Transperineal (TP) biopsy 
approach was followed. This reflects the general trend 
towards increasing use of TP biopsy due to its lower 
adverse effect profile and ability to access all areas of 
the prostate [24]. The need for a confirmatory biopsy in 
tertiary centre referrals was also debated, with no clear 
opinion reached; however the importance of concord-
ance between mpMRI and biopsy findings was felt to be 
vital in reassuring the clinicians and the patient that an 
accurate diagnosis has been made.
Prognostication of localised prostate cancer
A clear challenge for clinicians treating men with local-
ised prostate cancer at the present time is accurately 
assessing the risk of disease progression in men with 
Gleason score 3 + 4/Gleason Grade Group 2, and rec-
ommending the appropriate treatment. The risks of 
morbidity from radical treatment versus the risks of 
disease progression on AS are often finely balanced. 
This was a particularly contentious issue for the panel, 
and no consensus was reached. The agreed statements 
in Table  2 could be considered conservative in their 
approach, but the majority of panel members were 
more comfortable with not recommending AS as the 
optimal treatment option to a patient given there is 
currently no reliable way of distinguishing lethal from 
non-lethal prostate cancer for these men.
Strengths and limitations
This modified Delphi study was conducted in a meth-
odologically rigorous manner. A diverse panel of inter-
national prostate cancer experts was assembled, with an 
optimal number of participants who engaged through-
out the whole process. Agreement was achieved on the 
consensus statements through robust discussion and 
iterative work over two rounds of questionnaires, fol-
lowed by a face-to-face workshop to refine the criteria 
[25]. The panel has developed a set of practical recom-
mendations that take into consideration the latest evi-
dence in the field. The role of certain tests, including 
number of positive cores and Free:Total PSA ratio, in 
patient selection for AS was not agreed by the panel, 
although this could be considered to be a reflection of 
the current state of the evidence in these areas [15].
Conclusions
Active surveillance is an appropriate treatment option 
for men with localised, low-risk prostate cancer. It can be 
utilised to achieve good outcomes for patients and avoid 
overtreatment. It is vital that complete and accurate diag-
nostic information is obtained to ensure that the correct 
patients are recommended to undergo AS, and a patient’s 
suitability and treatment preferences are factored into the 
shared decision-making process. The findings of cohort 
studies of patients receiving AS that are currently on-
going will help to fill some of the evidence gaps around 
patient selection and follow-up protocols that exist today.
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